DNA甲基化预测宫颈病变研究进展

doi:10.12280/gjfckx.20201124

摘要/Abstract

摘要：

现有研究认为宫颈癌前病变进展到宫颈癌需要数十年时间,因此宫颈癌是一种可防控的妇科恶性肿瘤,其预防的关键在于尽早筛查出宫颈病变。基于我国国情,大部分宫颈病变筛查仍选用单一的薄层液基细胞学检查（TCT）或用人乳头瘤病毒（HPV）DNA检测分流TCT结果异常的方式,造成了临床工作中宫颈病变的漏诊或过度诊断。选择最优的筛查方式提高宫颈病变的诊断率是目前宫颈癌防控中亟待解决的问题。DNA甲基化调控的基因表观遗传学累积改变可能介导或预测恶性肿瘤的进展,其致癌的关键机制在于通过启动子沉默抑制基因表达导致整体低甲基化和基因特异性高甲基化,在宫颈病变中已被证实存在特定基因的甲基化水平升高。由于DNA甲基化具有高特异性,现阶段其正被开发作为宫颈病变筛查的标志物。现对相关基因甲基化预测宫颈病变进行综述。

关键词: 宫颈肿瘤, DNA甲基化, 癌前状态, 普查, 诊断

Abstract:

Existing studies suggest that it takes decades for cervical precancerous lesions to progress to cervical cancer. Therefore, cervical cancer is a preventable gynecological malignant tumor, and the key to its prevention is to screen out cervical lesions as soon as possible. Based on China′s national conditions, the majority of cervical lesions screening still choose a single thin-prep cytology test(TCT) examination or HPV DNA detection to shunt TCT results abnormal way, resulting in missed diagnosis or over diagnosis of cervical lesions in clinical work. To choose the best screening method to improve the diagnosis rate of cervical lesions is an urgent problem in the prevention and control of cervical cancer. Epigenetic accumulation of genes regulated by DNA methylation may mediate or predict the progression of malignant tumors. The key mechanism of carcinogenesis lies in the suppression of gene expression through promoter silencing, leading to global hypomethylation and gene specific hypermethylation. It has been confirmed that there is an increase in the methylation level of specific genes in cervical lesions. Because of its high specificity, it is also developed as a new additional tool for cervical lesions screening. This article will make a brief review of the related gene methylation in predicting cervical lesions.

Key words: Uterine cervical neoplasms, DNA methylation, Precancerous conditions, Mass screening, Diagnosis

陈丛, 赵敏. DNA甲基化预测宫颈病变研究进展[J]. 国际妇产科学杂志, 2021, 48(5): 535-538.

CHEN Cong, ZHAO Min. Research Progress of DNA Methylation in Predicting Cervical Lesions[J]. Journal of International Obstetrics and Gynecology, 2021, 48(5): 535-538.

参考文献 30

[1]	Wang J, Elfström KM, Andrae B, et al. Cervical cancer case-control audit: Results from routine evaluation of a nationwide cervical screening program[J]. Int J Cancer, 2020,146(5):1230-1240. doi: 10.1002/ijc.32416. doi: 10.1002/ijc.32416
[2]	Overmeer RM, Louwers JA, Meijer CJ, et al. Combined CADM1 and MAL promoter methylation analysis to detect (pre-)malignant cervical lesions in high-risk HPV-positive women[J]. Int J Cancer, 2011,129(9):2218-2225. doi: 10.1002/ijc.25890. doi: 10.1002/ijc.25890 pmid: 21190187
[3]	梁月兰, 赵雪, 耿建祥, 等. 宫颈ASC-US、LSIL和HSIL中HPV感染型别分布的研究[J]. 国际检验医学杂志, 2018,39(1):59-62. doi: 10.3969/j.issn.1673-4130.2018.01.016. doi: 10.3969/j.issn.1673-4130.2018.01.016
[4]	Klaes R, Benner A, Friedrich T, et al. p16INK4a immunohistoche-mistry improves interobserver agreement in the diagnosis of cervical intraepithelial neoplasia[J]. Am J Surg Pathol, 2002,26(11):1389-1399. doi: 10.1097/00000478-200211000-00001. doi: 10.1097/00000478-200211000-00001
[5]	Penault-Llorca F, Radosevic-Robin N. Ki67 assessment in breast cancer: an update[J]. Pathology, 2017,49(2):166-171. doi: 10.1016/j.pathol.2016.11.006. doi: 10.1016/j.pathol.2016.11.006
[6]	Lu J, Song E, Ghoneim A, et al. Machine learning for assisting cervical cancer diagnosis: An ensemble approach[J]. Future Gener Comp Sy, 2020,106:199-205. doi: 10.1016/j.future.2019.12.033. doi: 10.1016/j.future.2019.12.033
[7]	Yadav N, Parveen S, Banerjee M. Potential of nano-phytochemicals in cervical cancer therapy[J]. Clin Chim Acta, 2020,505:60-72. doi: 10.1016/j.cca.2020.01.035. doi: 10.1016/j.cca.2020.01.035
[8]	李明珠, 魏丽惠. 甲基化检测在宫颈癌诊治中的意义[J]. 现代妇产科进展, 2019,28(9):704-705. doi: 10.13283/j.cnki.xdfckjz.2019.09.034. doi: 10.13283/j.cnki.xdfckjz.2019.09.034
[9]	Qin R, Cao L, Wang J, et al. Promoter Methylation of Ezrin and its Impact on the Incidence and Prognosis of Cervical Cancer[J]. Cell Physiol Biochem, 2018,50(1):277-287. doi: 10.1159/000494005. doi: 10.1159/000494005
[10]	Stubert J, Szewczyk M, Spitschak A, et al. Adenoviral mediated expression of anti-inflammatory progranulin by placental explants modulates endothelial cell activation by decrease of ICAM-1 expression[J]. Placenta, 2020,90:109-117. doi: 10.1016/j.placenta.2019.12.018. doi: 10.1016/j.placenta.2019.12.018
[11]	Lai HC, Lin YW, Huang TH, et al. Identification of novel DNA methylation markers in cervical cancer[J]. Int J Cancer, 2008,123(1):161-167. doi: 10.1002/ijc.23519. doi: 10.1002/ijc.23519
[12]	Nikolaidis C, Nena E, Panagopoulou M, et al. PAX1 methylation as an auxiliary biomarker for cervical cancer screening: a meta-analysis[J]. Cancer Epidemiol, 2015,39(5):682-686. doi: 10.1016/j.canep.2015.07.008. doi: 10.1016/j.canep.2015.07.008 pmid: 26234429
[13]	Liu H, Meng X, Wang J. Real time quantitative methylation detection of PAX1 gene in cervical cancer screening[J]. Int J Gynecol Cancer, 2020,30(10):1488-1492. doi: 10.1136/ijgc-2019-001144. doi: 10.1136/ijgc-2019-001144
[14]	Huang TH, Lai HC, Liu HW, et al. Quantitative analysis of methylation status of the PAX1 gene for detection of cervical cancer[J]. Int J Gynecol Cancer, 2010,20(4):513-519. doi: 10.1111/IGC.0b013e3181c7fe6e. doi: 10.1111/IGC.0b013e3181c7fe6e
[15]	Chen Y, Cui Z, Xiao Z, et al. PAX1 and SOX1 methylation as an initial screening method for cervical cancer: a meta-analysis of individual studies in Asians[J]. Ann Transl Med, 2016,4(19):365. doi: 10.21037/atm.2016.09.30. doi: 10.21037/atm.2016.09.30 pmid: 27826568
[16]	Lai HC, Ou YC, Chen TC, et al. PAX1/SOX1 DNA methylation and cervical neoplasia detection: a Taiwanese Gynecologic Oncology Group (TGOG) study[J]. Cancer Med, 2014,3(4):1062-1074. doi: 10.1002/cam4.253. doi: 10.1002/cam4.253
[17]	Huang J, Gao H, Tan HZ. SOX1 Promoter Hypermethylation as a Potential Biomarker for High-Grade Squamous Intraepithelial Neoplasia Lesion and Cervical Carcinoma: A Meta-Analysis With Trial Sequential Analysis[J]. Front Genet, 2020,11:633. doi: 10.3389/fgene.2020.00633. doi: 10.3389/fgene.2020.00633 pmid: 32849763
[18]	Rogeri CD, Silveira H, Causin RL, et al. Methylation of the hsa-miR-124, SOX1, TERT, and LMX1A genes as biomarkers for precursor lesions in cervical cancer[J]. Gynecol Oncol, 2018,150(3):545-551. doi: 10.1016/j.ygyno.2018.06.014. doi: 10.1016/j.ygyno.2018.06.014
[19]	Wu NY, Zhang X, Chu T, et al. High methylation of ZNF582 in cervical adenocarcinoma affects radiosensitivity and prognosis[J]. Ann Transl Med, 2019,7(14):328. doi: 10.21037/atm.2019.06.15. doi: 10.21037/atm.2019.06.15
[20]	Huang RL, Chang CC, Su PH, et al. Methylomic analysis identifies frequent DNA methylation of zinc finger protein 582 (ZNF582) in cervical neoplasms[J]. PLoS One, 2012,7(7):e41060. doi: 10.1371/journal.pone.0041060. doi: 10.1371/journal.pone.0041060
[21]	汤福想, 郎凯楠, 刘玉玲. PAX1和ZNF582甲基化在宫颈细胞学非典型鳞状细胞分层管理中的意义[J]. 中国生育健康杂志, 2020,31(4):345-349,357. doi: 10.3969/j.issn.1671-878X.2020.04.010. doi: 10.3969/j.issn.1671-878X.2020.04.010
[22]	Liou YL, Zhang TL, Yan T, et al. Combined clinical and genetic testing algorithm for cervical cancer diagnosis[J]. Clin Epigenetics, 2016,8:66. doi: 10.1186/s13148-016-0232-3. doi: 10.1186/s13148-016-0232-3
[23]	Khunamornpong S, Settakorn J, Sukpan K, et al. Performance of HPV DNA testing with hybrid capture 2 in triaging women with minor cervical cytologic abnormalities (ASC-US/LSIL) in Northern Thailand[J]. Asian Pac J Cancer Prev, 2014,15(24):10961-10966. doi: 10.7314/apjcp.2014.15.24.10961. doi: 10.7314/apjcp.2014.15.24.10961
[24]	Oranratanaphan S, Kobwitaya K, Termrungruanglert W, et al. Value of CCNA1 promoter methylation in triaging ASC-US cytology[J]. Asian Pac J Cancer Prev, 2020,21(2):473-477. doi: 10.31557/APJCP.2020.21.2.473. doi: 10.31557/APJCP.2020.21.2.473
[25]	Chujan S, Kitkumthorn N, Siriangkul S, et al. CCNA1 promoter methylation: a potential marker for grading Papanicolaou smear cervical squamous intraepithelial lesions[J]. Asian Pac J Cancer Prev, 2014,15(18):7971-7975. doi: 10.7314/apjcp.2014.15.18.7971. doi: 10.7314/apjcp.2014.15.18.7971
[26]	Bu Q, Wang S, Ma J, et al. The clinical significance of FAM19A4 methylation in high-risk HPV-positive cervical samples for the detection of cervical (pre)cancer in Chinese women[J]. BMC Cancer, 2018,18(1):1182. doi: 10.1186/s12885-018-4877-5. doi: 10.1186/s12885-018-4877-5
[27]	Holubekova V, Mersakova S, Grendar M, et al. The Role of CADM1 and MAL Promoter Methylation in Inflammation and Cervical Intraepithelial Neoplasia[J]. Genet Test Mol Biomarkers, 2020,24(5):256-263. doi: 10.1089/gtmb.2019.0188. doi: 10.1089/gtmb.2019.0188
[28]	殷爱军. DNA甲基化检测在宫颈癌筛查中的应用[D]. 济南:山东大学, 2016.
[29]	Kalantari M, Osann K, Calleja-Macias IE, et al. Methylation of human papillomavirus 16, 18, 31, and 45 L2 and L1 genes and the cellular DAPK gene: Considerations for use as biomarkers of the progression of cervical neoplasia[J]. Virology, 2014,448:314-321. doi: 10.1016/j.virol.2013.10.032. doi: 10.1016/j.virol.2013.10.032 pmid: 24314662
[30]	Clarke MA, Gradissimo A, Schiffman M, et al. Human Papillomavirus DNA Methylation as a Biomarker for Cervical Precancer: Consistency across 12 Genotypes and Potential Impact on Management of HPV-Positive Women[J]. Clin Cancer Res, 2018,24(9):2194-2202. doi: 10.1158/1078-0432.CCR-17-3251. doi: 10.1158/1078-0432.CCR-17-3251 pmid: 29420222